Fifteen New Medications Selected for Medicare Negotiation – One America News Network
OAN Staff Abril Elfi
4:08 PM – Friday, January 17, 2025
The Centers for Medicare and Medicaid Services (CMS) have selected 15 more drugs for price negotiation under Medicare.
Advertisement
Officials from the administration revealed that these additional 15 drugs were chosen alongside the original 10 previously negotiated. The CMS was given a deadline of February 1st to announce the new selections, making this early announcement come two weeks ahead of that timeline.
On Friday, the Biden Administration disclosed the names of drugs selected for negotiation, including Ozempic and Wegovy.
“Today, I’m pleased to announce that my Administration has chosen the next 15 drugs for negotiation on Medicare pricing. These medications treat conditions like diabetes and cancer, which many seniors across the nation depend on,” stated President Joe Biden.
The negotiation between Medicare and the pharmaceutical companies is expected to unfold over the coming months, with the newly negotiated prices set to take effect in 2027.
The drugs designated for negotiations include:
- Ozempic; Rybelsus; Wegovy, for Type 2 diabetes and weight management.
- Trelegy Ellipta, utilized for asthma treatment.
- Xtandi, a medication for prostate cancer.
- Pomalyst, used in chemotherapy.
- Ibrance, a treatment for breast cancer.
- Ofev, for idiopathic pulmonary fibrosis.
- Linzess, for chronic constipation.
- Calquence, a cancer treatment.
- Austedo; Austedo XR, targeting Huntington’s disease.
- Breo Ellipta, for chronic obstructive pulmonary disease (COPD).
- Tradjenta, a diabetes medication.
- Xifaxan, used for diarrhea and irritable bowel syndrome.
- Vraylar, an antipsychotic.
- Janumet; Janumet XR, used for diabetes management.
- Otezla, a treatment for psoriatic arthritis.
Approximately 2.3 million Medicare seniors are currently using semaglutide medications, including Ozempic, Rybelsus, and Wegovy from Novo Nordisk. According to Medicare, these drugs accounted for over $14 billion in coverage by the program last year, marking the highest expenditure in this selection round.
Manufacturers are required to finalize negotiation agreements by February 28th.
Stay updated! Get breaking news alerts directly to your inbox for free. Subscribe here: https://www.oann.com/alerts
Advertisements below
